The trademark name for one of the forms of botulinum toxin used in injections targeting facial wrinkles. Botox paralyzes facial muscles, such as those that cause frown lines, in order to soften wrinkles. In cosmetic applications, botulinum toxin is considered relatively safe and effective for reduction of facial wrinkles, especially in the uppermost third of the face. Commercial forms are marketed under the brand names Botox Cosmetic/Vistabel from Allergan, Dysport/Azzalure from Galderma and Ipsen, Xeomin/Bocouture from Merz, Jeuveau/Nuceiva from Evolus, manufactured by Daewoong in South Korea. DaxibotulinumtoxinA (Daxxify) was approved for medical use in the United States. In Europe, Letybo is also available, marketed by Croma and manufactured by Hugel in South Korea, along with the first liquid formulated botulinum toxin in Europe, Alluzience, from Galderma and Ipsen. The effects of current botulinum toxin injections for glabellar lines ('11's lines' between the eyes) typically last two to four months and in some cases, product-dependent, with some patients experiencing a longer duration of effect of up to 6 months or longer. Injection of botulinum toxin into the muscles under facial wrinkles causes relaxation of those muscles, resulting in the smoothing of the overlying skin. Smoothing of wrinkles is usually visible three to five days after injection, with maximum effect typically a week following injection. Muscles can be treated repeatedly to maintain the smoothed appearance.
Subscribe to our e-mails
Receive the latest news in skin care routines and innovations delivered to your Inbox.